The inhibitory effect of disulfiram encapsulated PLGA NPs on tumor growth: Different administration routes
- Resource Type
- Authors
- Shahab Faghihi; Ghazaleh Zarrinrad; Hamidreza Fasehee; Seyed H. Ghaffari; Seyed Mohammad Tavangar
- Source
- Materials scienceengineering. C, Materials for biological applications. 63
- Subject
- Male
Materials science
medicine.medical_treatment
Intraperitoneal injection
Transplantation, Heterologous
Bioengineering
Antineoplastic Agents
Apoptosis
02 engineering and technology
Pharmacology
Biomaterials
03 medical and health sciences
chemistry.chemical_compound
Mice
0302 clinical medicine
Polylactic Acid-Polyglycolic Acid Copolymer
Cell Line, Tumor
Neoplasms
PEG ratio
Disulfiram
medicine
Animals
Humans
Lactic Acid
Cytotoxicity
Toxicity Tests, Chronic
Drug Carriers
Mice, Inbred BALB C
Caspase 3
technology, industry, and agriculture
021001 nanoscience & nanotechnology
G1 Phase Cell Cycle Checkpoints
PLGA
chemistry
Mechanics of Materials
Folate receptor
030220 oncology & carcinogenesis
Injections, Intravenous
MCF-7 Cells
Nanoparticles
Female
0210 nano-technology
Drug carrier
Injections, Intraperitoneal
Polyglycolic Acid
medicine.drug
- Language
- ISSN
- 1873-0191
The strong anticancer activity of disulfiram is hindered by its rapid degradation in blood system. A novel folate-receptor-targeted poly (lactide-co-glycolide) (PLGA)-polyethylene glycol (PEG) nanoparticle (NP) is developed for encapsulation and delivery of disulfiram into breast cancer tumor using passive (EPR effect) and active (folate receptor) targeting. The anticancer activity of disulfiram and its effect on caspase-3 activity and cell cycle are studied. The administration of encapsulated PLGA NPs using intra-peritoneal, intravenous and intra-tumor routes is investigated using animal model. Disulfiram shows strong cytotoxicity against MCF7 cell line. The activity of caspase-3 inhibited with disulfiram via dose dependent manner while the drug causes cell cycle arrest in G0/G1 and S phase time-dependently. The encapsulated disulfiram shows higher activity in apoptosis induction as compared to free drug. In nontoxic dose of encapsulated disulfiram, the highest and lowest efficacy of NPs in tumor growth inhibition is observed for intravenous injection and intraperitoneal injection. It is suggested that administration of disulfiram by targeted PLGA nanoparticles using intravenous injection would present an alternative therapeutic approach for solid tumor treatment.